Log In
BCIQ
Print this Print this
 

DV230

  Manage Alerts
Collapse Summary General Information
Company Dynavax Technologies Corp.
DescriptionSecond generation TLR agonist
Molecular Target
Mechanism of Action 
Therapeutic ModalityAdjuvant
Latest Stage of DevelopmentPreclinical
Standard IndicationAdjuvant
Indication DetailsAdjuvant
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today